Quest Laboratories Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Quest Laboratories Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from operations for the half year ended 30th September 2026 is ₹5,533.55 lakhs, compared to ₹4,880.48 lakhs for the half year ended 30th September 2025. EBITDA for the quarter ended September 30, 2026: ₹1,073.52 Lakhs (calculated as Profit before tax ₹1,006.07 Lakhs + Finance cost ₹26.03 Lakhs + Depreciation ₹41.49 Lakhs).
From Quest Laboratories Ltd's Q2 FY27 earnings-call transcript · updated 11 Nov 2026.
How did Quest Laboratories' revenue grow in the September 2026 quarter?
- Revenue from operations for the half year ended 30th September 2026 is ₹5,533.55 lakhs, compared to ₹4,880.48 lakhs for the half year ended 30th September 2025.
- This reflects a year-on-year revenue growth of approximately 13.39%.
- Total income for the half year ended 30th September 2026 is ₹5,704.69 lakhs, up from ₹5,207.97 lakhs in the same period last year.
What happened to Quest Laboratories' margins in Q2 FY27?
See what Quest Laboratories Ltd said on profitability & margins — free account, 30 seconds.
What capex is Quest Laboratories planning?
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Quest Laboratories raising money or cutting debt?
See what Quest Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Quest Laboratories' order book?
See what Quest Laboratories Ltd said on order book & pipeline — free account, 30 seconds.
More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsRevenue ₹3770 Cr · PAT ₹1,127 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Bal Pharma (Q2 FY27)
Revenue from operations (Consolidated) for Q2 FY 2026-27: ₹8,994.69 lakhs, up from ₹7,402.49 lakhs in Q2 FY 2025-26, reflecting a year-on-year increase of…
- Bafna Pharmaceuticals (Q2 FY27)
INR 3,546.82 Lakhs, approximately 34.4% increase. Key results statement takeaways from Bafna Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks
- Haleos Labs Limited (Q2 FY27)
1,036.03 Lakhs (~13.3% growth). Key results statement takeaways from Haleos Labs Limited's Q2 FY27 results statement — and how it ranks against sector peers.
- Curis Lifesciences (Q2 FY27)
2790.89 lakh for the quarter ended 30.09.2025 (standalone), indicating a year-on-year increase of approximately 32.8%. Key results statement takeaways from Curi
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Quest Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Quest Laboratories Ltd Q2 FY27 results?
Revenue from operations for the half year ended 30th September 2026 is ₹5,533.55 lakhs, compared to ₹4,880.48 lakhs for the half year ended 30th September 2025. EBITDA for the quarter ended September 30, 2026: ₹1,073.52 Lakhs (calculated as Profit before tax ₹1,006.07 Lakhs + Finance cost ₹26.03 Lakhs + Depreciation ₹41.49 Lakhs).
What is Quest Laboratories Ltd share price analysis?
Quest Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 9.9 with a market cap of ₹147 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Quest Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.